In order to detect early-stage AKI and prediction of adverse clinical outcomes, new biomarkers are being studied in recent years, among them, both cystatin c and kidney injury molecule-1 (KIM-1) have shown some performance after CPB (4). The gene discussed is CST3; the disease is acute kidney injury.